Medications
FDA approves first biosimilar drug in US
(HealthDay)—The U.S. Food and Drug Administration has approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States.
Mar 8, 2015
0
6
Page 15 - News tagged with leukemia drug
Oncology & Cancer
Researchers to test 'breakthrough' pediatric leukemia treatment
A promising method of immunotherapy to treat children with relapsed acute lymphocytic leukemia (ALL) is opening at the University of Wisconsin Carbone Cancer Center and American Family Children's Hospital. The trial is open ...
Feb 25, 2015
0
14
Oncology & Cancer
Evolution may hold the key to more designer cancer drugs like Gleevec
This is the story of Abl and Src—two nearly identical protein kinases whose evolution may hold the key to unlocking new, highly specific cancer drugs.
Feb 19, 2015
1
107
Oncology & Cancer
New opportunity to treat drug-resistant leukemia discovered
A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration ...
Feb 9, 2015
1
46
Oncology & Cancer
Could there be a gleevec for brain cancer?
The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically ...
Feb 9, 2015
0
27
Medications
What should a hospital do when critical drugs are in short supply?
Four years ago, just before Christmas, my hospital ran out of cytarabine, an essential drug used to treat and cure certain kinds of acute leukemia. This drug was suddenly in short supply across the nation. At Duke, we had ...
Jan 7, 2015
0
5
Oncology & Cancer
Blincyto approved for rare leukemia
(HealthDay)—Blincyto (blinatumomab) has been approved by the U.S. Food and Drug Administration to treat Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, a rare cancer of the bone marrow.
Dec 3, 2014
0
0
Oncology & Cancer
'Dramatic' early phase 1 results for AG-120 in IDH1 mutated AML
Results presented November 19 by University of Colorado Cancer Center investigator Daniel Pollyea, MD, MS, at the 26th European Organisation for Research and Treatment of Cancer Symposium in Barcelona show "extremely promising" ...
Nov 25, 2014
0
0
Oncology & Cancer
A new approach to fighting chronic myeloid leukemia
Chronic myeloid leukemia develops when a gene mutates and causes an enzyme to become hyperactive, causing blood-forming stem cells in the bone marrow to grow rapidly into abnormal cells. The enzyme, Abl-kinase, is a member ...
Nov 17, 2014
0
0
Oncology & Cancer
Study finds a new approach to tackle drug resistance in hematologic malignancies
Treating hematologic malignancies upfront with a combination of drugs based on the vulnerabilities of tumors as they evolve may be a viable strategy to avoid drug resistance, according to data presented at the American Association ...
Sep 23, 2014
0
0
